The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis
Standard
The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. / Iking-Konert, Christof; Wallmeier, Pia; Arnold, Sabrina; Adler, Sabine; de Groot, Kirsten; Hellmich, Bernhard; Hoyer, Bimba F; Holl-Ulrich, Konstanze; Ihorst, Gabriele; Kaufmann, Margit; Kötter, Ina; Müller-Ladner, Ulf; Magnus, T; Rech, Jürgen; Schubach, Fabian; Schulze-Koops, Hendrik; Venhoff, Nils; Wiech, Thorsten; Villiger, Peter; Lamprecht, Peter.
in: BMC RHEUMATOL, Jahrgang 5, Nr. 1, 40, 31.07.2021.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis
AU - Iking-Konert, Christof
AU - Wallmeier, Pia
AU - Arnold, Sabrina
AU - Adler, Sabine
AU - de Groot, Kirsten
AU - Hellmich, Bernhard
AU - Hoyer, Bimba F
AU - Holl-Ulrich, Konstanze
AU - Ihorst, Gabriele
AU - Kaufmann, Margit
AU - Kötter, Ina
AU - Müller-Ladner, Ulf
AU - Magnus, T
AU - Rech, Jürgen
AU - Schubach, Fabian
AU - Schulze-Koops, Hendrik
AU - Venhoff, Nils
AU - Wiech, Thorsten
AU - Villiger, Peter
AU - Lamprecht, Peter
N1 - © 2021. The Author(s).
PY - 2021/7/31
Y1 - 2021/7/31
N2 - BACKGROUND: Vasculitides comprise a group of rare diseases which affect less than 5 in 10.000 individuals. Most types of vasculitis can become organ- and life-threatening and are characterized by chronicity, high morbidity and relapses, altogether resulting in significant morbidity and mortality. Previous studies have been either monocentric or mainly retrospective - studies with a prospective design mostly consisted of rather small cohorts of 100 to 200 patients. The aim of the Joint Vasculitis Registry in German-speaking countries (GeVas) is to record all patients who have been recently diagnosed with vasculitis or who have changed their treatment due to a relapse (inception cohort). In GeVas, data are collected prospectively in a multicenter design in Germany, Austria and Switzerland. By this approach, courses of vasculitis and their outcomes can be monitored over an extended period.METHODS: GeVas is a prospective, web-based, multicenter, clinician-driven registry for the documentation of organ manifestations, damage, long-term progress and other outcomes of various types of vasculitis. The registry started recruiting in June 2019. As of October 2020, 14 centers have been initiated and started recruiting patients in Germany. Involvement of sites in Austria and the German-speaking counties of Switzerland is scheduled in the near future.DISCUSSION: In June 2019, we successfully established a prospective multicenter vasculitis registry being the first of its kind in German-speaking countries. The participating centers are currently recruiting, and systematic analysis of long-term vasculitis outcomes is expected in the ensuing period.TRIAL REGISTRATION: German Clinical Trials Register (Deutsches Register Klinischer Studien): DRKS00011866 . Registered 10 May 2019.
AB - BACKGROUND: Vasculitides comprise a group of rare diseases which affect less than 5 in 10.000 individuals. Most types of vasculitis can become organ- and life-threatening and are characterized by chronicity, high morbidity and relapses, altogether resulting in significant morbidity and mortality. Previous studies have been either monocentric or mainly retrospective - studies with a prospective design mostly consisted of rather small cohorts of 100 to 200 patients. The aim of the Joint Vasculitis Registry in German-speaking countries (GeVas) is to record all patients who have been recently diagnosed with vasculitis or who have changed their treatment due to a relapse (inception cohort). In GeVas, data are collected prospectively in a multicenter design in Germany, Austria and Switzerland. By this approach, courses of vasculitis and their outcomes can be monitored over an extended period.METHODS: GeVas is a prospective, web-based, multicenter, clinician-driven registry for the documentation of organ manifestations, damage, long-term progress and other outcomes of various types of vasculitis. The registry started recruiting in June 2019. As of October 2020, 14 centers have been initiated and started recruiting patients in Germany. Involvement of sites in Austria and the German-speaking counties of Switzerland is scheduled in the near future.DISCUSSION: In June 2019, we successfully established a prospective multicenter vasculitis registry being the first of its kind in German-speaking countries. The participating centers are currently recruiting, and systematic analysis of long-term vasculitis outcomes is expected in the ensuing period.TRIAL REGISTRATION: German Clinical Trials Register (Deutsches Register Klinischer Studien): DRKS00011866 . Registered 10 May 2019.
U2 - 10.1186/s41927-021-00206-2
DO - 10.1186/s41927-021-00206-2
M3 - SCORING: Journal article
C2 - 34330340
VL - 5
JO - BMC RHEUMATOL
JF - BMC RHEUMATOL
SN - 2520-1026
IS - 1
M1 - 40
ER -
